Articles

Key View

• UK drug shortages will likely persist due to ongoing post-Brexit access challenges, alongside wider regional supply chain issues. 
• The UK's pharmaceutical sector will continue to present a less attractive prospect for investment compared to EU markets.
• Amidst Brexit's complexities, the UK government will continue to introduce new measures to

Please Note: BMI is enhancing its risk analysis with a new scoring system following its acquisition of GeoQuant, a market-leading provider of political risk data. From March 27 2024, risk scores are inverted: zero now represents the lowest risk and 100 represents the highest risk. This allows for clearer, industry-standard assessments. For further

Key View: Over 2024, we forecast total arrivals to Mauritius to reach 1.5mn, up from 1.3mn arrivals in 2023, growing by 14.2% y-o-y. We expect Mauritius’ 2024 arrivals to fully recover to pre-Covid levels in 2019, while surpassing the historic peak in 2018. Arrivals will continue to increase over the medium term (2024-2028) with the market’s beach

Key View

• We retain our view that the Bank of Botswana (BoB) will hold its policy rate at 2.40% over the remainder of 2024, following the decision to hold the benchmark monetary policy rate steady on April 26.
• Inflation is expected to trend near the lower end of the BoB’s 3.0-6.0% inflation target range over the coming quarters, underpinning our

Key View: Our outlook for German consumer spending over 2024 shows a slight yet modest rebound yet remains below pre-pandemic levels. Consumer confidence is stable but subdued, with retail sales weak amid ongoing economic challenges. Inflation pressures are expected to ease, while the labour market is relatively tight. Government interventions

Commodities displayed a stellar performance in April 2024 thus far, in general, with more sub-asset classes now seeing price appreciation in the year-to-date than not. 

In the main, renewed US dollar strength as markets continue to push back expectations for US Federal Reserve (Fed) rate cuts has failed to substantially pressure commodities priced

The Latest: On April 22, 2024, the European Commission (EC) granted approval to Samsung Bioepis’s Pyzchiva (ustekinumab), a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), thereby broadening the range of treatment options for patients with chronic inflammatory conditions. Pyzchiva is indicated for the treatment of plaque psoriasis

The Latest: In May 2024, AB Living which is a Spain-based property development group announced plans to open a new Almare resort in Isla Mujeres, Mexico in partnership with US-based hotels and resorts company Marriott International. The all-inclusive adult-only resort will be part of Marriott's Luxury Collection and will include 150-rooms, with